Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Overview of ovulation induction

Bart CJM Fauser, MD, PhD
Section Editors
Robert L Barbieri, MD
William F Crowley, Jr, MD
Deputy Editor
Kathryn A Martin, MD


Ovulatory disorders can be identified in 18 to 25 percent of couples presenting with infertility [1]. Most of these women have oligomenorrhea, arbitrarily defined as menstruation that occurs at intervals of 35 days to six months. While ovulation may occasionally occur, spontaneous conception is unlikely.

This topic will review the efficacy of the different regimens used for ovulation induction in women with ovulatory disorders (clomiphene citrate, gonadotropins, pulsatile gonadotropin-releasing hormone [GnRH] therapy, aromatase inhibitors, and dopamine agonists) and provide our approach to the management of such women. Some of these drugs are reviewed in greater detail elsewhere, and assisted reproductive technologies are also discussed elsewhere. (See "Ovulation induction with clomiphene citrate" and "Ovulation induction with letrozole" and "In vitro fertilization".)


The clinical approach to ovulation induction requires an understanding of the causes of anovulation. The World Health Organization (WHO) classified different categories of anovulation into three categories:

WHO class 1: Hypogonadotropic hypogonadal anovulation (hypothalamic amenorrhea [HA]) (See "Evaluation and management of secondary amenorrhea" and "Amenorrhea and infertility associated with exercise".)

WHO class 2: Normogonadotropic normoestrogenic anovulation (almost all women in this category have polycystic ovary syndrome [PCOS]), when using the Rotterdam criteria for the diagnosis of PCOS [2] (see "Diagnosis of polycystic ovary syndrome in adults", section on 'Diagnosis')


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Feb 8, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Hull MG, Glazener CM, Kelly NJ, et al. Population study of causes, treatment, and outcome of infertility. Br Med J (Clin Res Ed) 1985; 291:1693.
  2. Daan NM, Louwers YV, Koster MP, et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil Steril 2014; 102:1444.
  3. De Souza MJ, Miller BE, Loucks AB, et al. High frequency of luteal phase deficiency and anovulation in recreational women runners: blunted elevation in follicle-stimulating hormone observed during luteal-follicular transition. J Clin Endocrinol Metab 1998; 83:4220.
  4. Laven JS, Imani B, Eijkemans MJ, Fauser BC. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv 2002; 57:755.
  5. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41.
  6. Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002; 13:251.
  7. Boomsma CM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12:673.
  8. de Wilde MA, Veltman-Verhulst SM, Goverde AJ, et al. Preconception predictors of gestational diabetes: a multicentre prospective cohort study on the predominant complication of pregnancy in polycystic ovary syndrome. Hum Reprod 2014; 29:1327.
  9. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 2010; 376:911.
  10. Eijkemans MJ, Imani B, Mulders AG, et al. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod 2003; 18:2357.
  11. Martin KA, Hall JE, Adams JM, Crowley WF Jr. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea. J Clin Endocrinol Metab 1993; 77:125.
  12. Veltman-Verhulst SM, Fauser BC, Eijkemans MJ. High singleton live birth rate confirmed after ovulation induction in women with anovulatory polycystic ovary syndrome: validation of a prediction model for clinical practice. Fertil Steril 2012; 98:761.
  13. KISTNER RW, SMITH OW. Observations on the use of a non-steroidal estrogen antagonist: MER-25. Surg Forum 1960; 10:725.
  14. Imani B, Eijkemans MJ, te Velde ER, et al. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 2002; 77:91.
  15. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001; 75:305.
  16. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014; 371:119.
  17. Franik S, Kremer JA, Nelen WL, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2014; :CD010287.
  18. Fauser BC. Reproductive endocrinology: revisiting ovulation induction in PCOS. Nat Rev Endocrinol 2014; 10:704.
  19. Weil C. The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Curr Med Res Opin 1986; 10:172.
  20. Martin K, Santoro N, Hall J, et al. Clinical review 15: Management of ovulatory disorders with pulsatile gonadotropin-releasing hormone. J Clin Endocrinol Metab 1990; 71:1081A.
  21. Filicori M, Flamigni C, Dellai P, et al. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab 1994; 79:1215.
  22. Lunenfeld B. Historical perspectives in gonadotrophin therapy. Hum Reprod Update 2004; 10:453.
  23. Hughes E, Collins J, Vandekerckhove P. Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. Cochrane Database Syst Rev 2000; :CD000087.
  24. Nugent D, Vandekerckhove P, Hughes E, et al. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2000; :CD000410.
  25. Bayram N, van Wely M, van Der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2001; :CD002121.
  26. European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 2001; 86:2607.
  27. Devroey P, Boostanfar R, Koper NP, et al. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009; 24:3063.
  28. Ludwig M, Doody KJ, Doody KM. Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril 2003; 79:1051.
  29. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997; 18:71.
  30. White DM, Polson DW, Kiddy D, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 1996; 81:3821.
  31. Balen AH, Braat DD, West C, et al. Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients. Hum Reprod 1994; 9:1563.
  32. Homburg R, Levy T, Ben-Rafael Z. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil Steril 1995; 63:729.
  33. Hedon B, Hugues JN, Emperaire JC, et al. A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women. Hum Reprod 1998; 13:2688.
  34. van Santbrink EJ, Donderwinkel PF, van Dessel TJ, Fauser BC. Gonadotrophin induction of ovulation using a step-down dose regimen: single-centre clinical experience in 82 patients. Hum Reprod 1995; 10:1048.
  35. Imani B, Eijkemans MJ, Faessen GH, et al. Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil Steril 2002; 77:83.
  36. Buvat J, Buvat-Herbaut M, Marcolin G, et al. Purified follicle-stimulating hormone in polycystic ovary syndrome: slow administration is safer and more effective. Fertil Steril 1989; 52:553.
  37. Shoham Z, Patel A, Jacobs HS. Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone. Fertil Steril 1991; 55:1051.
  38. Calaf Alsina J, Ruiz Balda JA, Romeu Sarrió A, et al. Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial. BJOG 2003; 110:1072.
  39. van Santbrink EJ, Fauser BC. Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens. J Clin Endocrinol Metab 1997; 82:3597.
  40. Balasch J, Fábregues F, Creus M, et al. Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens. Hum Reprod 2001; 16:652.
  41. Christin-Maitre S, Hugues JN, Recombinant FSH Study Group. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod 2003; 18:1626.
  42. Hugues JN, Cédrin-Durnerin I, Avril C, et al. Sequential step-up and step-down dose regimen: an alternative method for ovulation induction with follicle-stimulating hormone in polycystic ovarian syndrome. Hum Reprod 1996; 11:2581.
  43. Mulders AG, Eijkemans MJ, Imani B, Fauser BC. Prediction of chances for success or complications in gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility. Reprod Biomed Online 2003; 7:170.
  44. Mulders AG, Laven JS, Imani B, et al. IVF outcome in anovulatory infertility (WHO group 2)--including polycystic ovary syndrome--following previous unsuccessful ovulation induction. Reprod Biomed Online 2003; 7:50.
  45. Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet 2005; 365:1807.
  46. Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331:771.
  47. Shushan A, Paltiel O, Iscovich J, et al. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996; 65:13.
  48. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155:217.
  49. Bristow RE, Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril 1996; 66:499.
  50. Venn A, Watson L, Bruinsma F, et al. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999; 354:1586.
  51. Modan B, Ron E, Lerner-Geva L, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998; 147:1038.
  52. Calderon-Margalit R, Friedlander Y, Yanetz R, et al. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol 2009; 169:365.
  53. Kashyap S, Moher D, Fung MF, Rosenwaks Z. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 2004; 103:785.
  54. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 2004; 103:1194.
  55. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004; 82:405.
  56. Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev 2013; :CD008215.
  57. Rodriguez C, Tatham LM, Calle EE, et al. Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Cancer Causes Control 1998; 9:645.
  58. American College of Obstetricians and Gynecologists. Management of infertility caused by ovulatory dysfunction. ACOG practice bulletin #34. American College of Obstetricians and Gynecologists, Washington, DC 2002.
  59. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1212.
  60. Rossing MA, Tang MT, Flagg EW, et al. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 2004; 160:1070.
  61. Ricci E, Parazzini F, Negri E, et al. Fertility drugs and the risk of breast cancer. Hum Reprod 1999; 14:1653.
  62. Rossing MA, Daling JR, Weiss NS, et al. Risk of breast cancer in a cohort of infertile women. Gynecol Oncol 1996; 60:3.
  63. Doyle P, Maconochie N, Beral V, et al. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002; 17:2209.
  64. Brinton LA, Scoccia B, Moghissi KS, et al. Breast cancer risk associated with ovulation-stimulating drugs. Hum Reprod 2004; 19:2005.
  65. Gauthier E, Paoletti X, Clavel-Chapelon F, E3N group. Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study. Hum Reprod 2004; 19:2216.
  66. Burkman RT, Tang MT, Malone KE, et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study. Fertil Steril 2003; 79:844.
  67. Terry KL, Willett WC, Rich-Edwards JW, Michels KB. A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch Intern Med 2006; 166:2484.
  68. Fei C, Deroo LA, Sandler DP, Weinberg CR. Fertility drugs and young-onset breast cancer: results from the Two Sister Study. J Natl Cancer Inst 2012; 104:1021.
  69. Althuis MD, Scoccia B, Lamb EJ, et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol 2005; 193:668.
  70. Brinton LA, Krüger Kjaer S, Thomsen BL, et al. Childhood tumor risk after treatment with ovulation-stimulating drugs. Fertil Steril 2004; 81:1083.